Semintra - is a medication that contains telmisartan, aimed at reducing the amount of protein lost by the cat's body through urine.
Clinical experience shows that a decrease in proteinuria can be observed as early as within the first 7 days of treatment.
The mechanism of action of telmisartan lies in its ability to displace angiotensin II from binding to the AT1 receptor. It selectively binds to the AT1 receptor and does not interact with other types of AT receptors. This reduces the pathological effects of angiotensin II, such as vasoconstriction, sodium and water retention, increased aldosterone synthesis, and changes in organs associated with angiotensin II. Importantly, the stimulation of the AT2 receptor is not suppressed, which helps maintain normal physiological processes such as vasodilation and natriuresis. The receptor binding is sustained for a long time due to the slow dissociation of telmisartan.
APPLICATION AND DOSAGE
For cats over 6 months of age, administered orally, daily, at a dose of 0.25 ml per kg of body weight.
